Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 180

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study

Open access
Sánchez-Guijo, Fermín, García-Arranz, Mariano, López-Parra, Miriam, Monedero, Pablo, Mata-Martínez, Carmen, Santos, Arnoldo, Sagredo, Víctor, Álvarez-Avello, José-Manuel, Guerrero, José Eugenio, Pérez-Calvo, César, Sánchez-Hernández, Miguel-Vicente, Del-Pozo, José Luis, Andreu, Enrique J., Fernández-Santos, María-Eugenia, Soria-Juan, Barbara, Hernández-Blasco, Luis M., Andreu, Etelvina, Sempere, José M., Zapata, Agustín G., Moraleda, José M., Soria, Bernat, Fernández-Avilés, Francisco, García-Olmo, Damián, Prósper, Felipe·2020·EClinicalMedicine

Abstract

Background Identification of effective treatments in severe cases of COVID-19 requiring mechanical ventilation represents an unmet medical need. Our aim was to determine whether the administration of adipose-tissue derived mesenchymal stromal cells (AT-MSC) is safe and potentially useful in these patients. Methods Thirteen COVID-19 adult patients under invasive mechanical ventilation who had received previous antiviral and/or anti-inflammatory treatments (including steroids, lopinavir/ritonavir, hydroxychloroquine and/or tocilizumab, among others) were treated with allogeneic AT-MSC. Ten patients received two doses, with the second dose administered a median of 3 days (interquartile range-IQR- 1 day) after the first one. Two patients received a single dose and another patient received 3 doses. Median number of cells per dose was 0.98 × 10 6 (IQR 0.50 × 10 6 ) AT-MSC/kg of recipient's body weight. Potential adverse effects related to cell infusion and clinical outcome were assessed. Additional parameters analyzed included changes in imaging, analytical and inflammatory parameters. Findings First dose of AT-MSC was administered at a median of 7 days (IQR 12 days) after mechanical ventilation. No adverse events were related to cell therapy. With a median follow-up of 16 days (IQR 9 days) after the first dose, clinical improvement was observed in nine patients (70%). Seven patients were extubated and discharged from ICU while four patients remained intubated (two with an improvement in their ventilatory and radiological parameters and two in stable condition). Two patients died (one due to massive gastrointestinal bleeding unrelated to MSC therapy). Treatment with AT-MSC was followed by a decrease in inflammatory parameters (reduction in C-reactive protein, IL-6, ferritin, LDH and d-dimer) as well as an increase in lymphocytes, particularly in those patients with clinical improvement. Interpretation Treatment with intravenous administration of AT-MSC in 13 severe COVID-19 pneumonia under mechanical ventilation in a small case series did not induce significant adverse events and was followed by clinical and biological improvement in most subjects. Funding None.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eclinm.2020.100454

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Metadata

Authors
Sánchez-Guijo, F., García-Arranz, M., López-Parra, M., Monedero, P., Mata-Martínez, C., Santos, A., Sagredo, V., Álvarez-Avello, J.-M., Guerrero, J. E., Pérez-Calvo, C., Sánchez-Hernández, M.-V., Del-Pozo, J. L., Andreu, E. J., Fernández-Santos, M.-E., Soria-Juan, B., Hernández-Blasco, L. M., Andreu, E., Sempere, J. M., Zapata, A. G., Moraleda, J. M., Soria, B., Fernández-Avilés, F., García-Olmo, D., & Prósper, F.
Venue
EClinicalMedicine
Publisher
Elsevier BV
Published
2020-08
Volume
25
Pages
100454
ISSN
2589-5370 (ISSN-L)
OpenAlex
W3041428009
Cited by
180
References
8
FWCI
16.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. https://app.cochat.ai/papers/10.1016/j.eclinm.2020.100454
The paper
Sánchez-Guijo, F., García-Arranz, M., López-Parra, M., Monedero, P., Mata-Martínez, C., Santos, A., Sagredo, V., Álvarez-Avello, J.-M., Guerrero, J. E., Pérez-Calvo, C., Sánchez-Hernández, M.-V., Del-Pozo, J. L., Andreu, E. J., Fernández-Santos, M.-E., Soria-Juan, B., Hernández-Blasco, L. M., Andreu, E., Sempere, J. M., Zapata, A. G., . . . Prósper, F. (2020). Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2020.100454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.